To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Sofosbuvir/velpatasvir fo… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden

Journal article
Authors V. Isakov
V. Chulanov
D. Abdurakhmanov
E. Burnevich
E. Nurmukhametova
G. Kozhevnikova
N. Gankina
S. Zhuravel
S. Romanova
R. H. Hyland
S. Lu
E. S. Svarovskaia
J. McNally
D. M. Brainard
V. Ivashkin
V. Morozov
I. Bakulin
Martin Lagging
K. Zhdanov
O. Weiland
Published in Infectious Diseases
Volume 51
Issue 2
Pages 131-139
ISSN 2374-4235
Publication year 2019
Published at Institute of Biomedicine, Department of Infectious Medicine
Pages 131-139
Language en
Keywords Direct-acting antivirals, hepatitis C virus, pangenotypic, sofosbuvir, sustained virologic response, patient-reported outcomes, chronic hepatitis-c, future disease burden, virus-infection, genotype 1, sofosbuvir, velpatasvir, ribavirin, efficacy, boceprevir, Infectious Diseases
Subject categories Internal medicine


Background: In both Russia and Sweden, the dominant hepatitis C virus (HCV) is genotype 1, but around one-third of patients have genotype 3 infection. For such countries, HCV genotype testing is recommended prior to therapy. An effective pangenotypic therapy may potentially eliminate the need for genotyping. In this study, we evaluated the efficacy and safety of sofosbuvir/velpatasvir for 12 weeks in patients from Russia and Sweden. Methods: In an open-label, single-arm phase-3 study, patients could have HCV genotype 1-6 infection and were treatment-naive or interferon treatment-experienced. All patients received sofosbuvir/velpatasvir, once daily for 12 weeks. The primary endpoint was sustained virologic response 12 weeks post-treatment (SVR12). Results: Of 122 patients screened, 119 were enrolled and treated. Overall, half (50%) were male, 18% had cirrhosis, and 24% had failed prior interferon-based therapy. In total, 66% of patients were infected with HCV genotype 1 (59% 1b and 7% 1a), 6% with genotype 2, and 29% with genotype 3. The overall SVR12 rate was 99% (118/119, 95% confidence interval 95-100%). One treatment-experienced patient infected with HCV genotype 3 experienced virologic relapse after completing treatment. The most common adverse events were headache (16%) and fatigue (7%). Serious adverse events were observed in four patients, but none were related to treatment. No patients discontinued treatment due to adverse events. Conclusion: Sofosbuvir/velpatasvir as a pangenotypic treatment for 12 weeks was highly effective in patients from Russia and Sweden infected with HCV genotypes 1, 2, or 3. Sofosbuvir/velpatasvir was safe and well-tolerated.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?